SRL
ONCY

Scientech Research LLC’s Oncolytics Biotech ONCY Stock Holding History

Scientech Research LLC’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,204
Closed -$25.5K – 721
2025
Q3 		$25.5K Buy
+18,204
New +$20.4K 0.01% 530

Other funds holding ONCY

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

Scientech Research LLC's ONCY Position: Q4 2025 in Review

Scientech Research LLC sold out of Oncolytics Biotech (ONCY) in Q4 2025, closing a stake of 18,204 shares — an estimated $25.5K sold.

Scientech Research LLC first reported a position in ONCY in Q3 2025 and held it in 1 quarter. The position peaked at $25.5K in Q3 2025. 61 funds tracked by Wall St. Rank hold ONCY as of Q4 2025.

  • Scientech Research LLC reported no remaining Oncolytics Biotech position as of Q4 2025 after selling out during the quarter.
  • Scientech Research LLC sold 18,204 Oncolytics Biotech shares in Q4 2025, an estimated $25.5K.
  • Scientech Research LLC first reported a position in Oncolytics Biotech in Q3 2025 and held it in 1 quarter.
  • Scientech Research LLC's Oncolytics Biotech position peaked at $25.5K in Q3 2025.
  • 61 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q4 2025.

Based on Scientech Research LLC's 13F filing for Q4 2025, filed 17 Feb 2026.